Citations 3
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Michaelson, M. Dror , Nandagopal, Lakshminarayanan , George, Saby , Alva, Ajjai , Harrison, Michael R. , Sosman, Jeffrey A. , Bhayani, Sam B., Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Kyriakopoulos, Christos E. , LaGrange, Chad A. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, McDonald, Andrew , Mortazavi, Amir , Ponsky, Lee , Redman, Bruce G., Somer, Bradley G. , Wile, Geoffrey, Dwyer, Mary A., CGC, Hammond, Lydia J., Zuccarino-Catania, Griselda, Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Gore, John L. , Haas, Naomi B , Plimack, Elizabeth R. , Agarwal, Neeraj , Gallagher, Thomas H. , Hancock, Steven Lee , Lam, Elaine T. , Manley, Brandon J. , Pierorazio, Phillip , CGC
Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1278-1285
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, Martin S. , Wang, Eunice S. , Altman, Jessica K. , Appelbaum, Frederick R. , Bixby, Dale L. , Coutré, Steven , Fathi, Amir T. , Fiorella, Melanie, Foran, James M. , Hall, Aric C. , Jacoby, Meagan A., LeBlanc, Thomas W. , Mannis, Gabriel N. , Marcucci, Guido , Martin, Michael G. , O’Donnell, Margaret, Olin, Rebecca L. , Peker, Deniz , Perl, Alexander E. , Pratz, Keith W. , Shami, Paul J. , Stone, Richard M. , Strickland, Stephen A. , Wieduwilt, Matthew J. , Gregory, Kristina M., OCN, Hammond, Lydia J., Ogba, Ndiya , Wang, Eunice S. , Strickland, Stephen Anthony , Leblanc, Thomas , Bhatt, Vijaya Raj , Lima, Marcos de , Lancet, Jeffrey E. , Mims, Alice S , Pollyea, Daniel Aaron , Prébet, Thomas , Ravandi, Farhad , OCN
Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 721-749
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav
Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.